Health Care • Biotechnology: Pharmaceutical Preparations
$3.24 ▼ -0.06
(-1.82%)
MKT CAP: $188.1M • VOL: 153.4K
52W L $2 52W H $6
WHWK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $7.1M | $26.0M | $24.4M |
| YoY Revenue Growth % | -72.5% | +6.7% | — |
| Gross Profit | $6.4M | $23.0M | — |
| Gross Margin % | 89.4% | 88.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$114.4M | -$67.5M | -$71.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$20.6M | -$63.7M | -$65.8M |
| EBITDA (Normalized) | -$114.0M | -$66.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$97.4M | -$59.5M | -$59.7M |
| Capital Expenditures (CapEx) | $552.0K | $1.7M | — |
| Free Cash Flow (FCF) | -$98.0M | -$61.2M | -$59.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $37.6M | $28.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $136.3M | $52.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR WHWK.